Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

USAntibiotics Appoints Eric Wesoloski Vice President of Quality and Regulatory Affairs


USAntibiotics, the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Eric Wesoloski to the position of vice president of quality and regulatory affairs. In this role, Wesoloski leads all aspects of quality assurance and control, compliance, regulatory affairs and pharmacovigilance related to the manufacturing, packaging, distribution and post-marketing requirements for the company's antibiotics.

With more than 30 years in the life sciences industry, Wesoloski's experience spans markets that include biologics, nutraceuticals, medical devices and pharmaceuticals. He is a recognized global quality leader, known for building best-in-class teams and processes that foster operational excellence, adhere to the highest quality standards, and meet U.S. Food and Drug Administration (FDA) regulatory compliance requirements.

"We are pleased to welcome Eric Wesoloski to USAntibiotics as vice president of quality and regulatory affairs," said Patrick Cashman, president, USAntibiotics. "Eric's extensive experience in the life sciences industry, coupled with a proven track record of building robust quality assurance systems, reinforces our strong commitment to upholding the highest standards in pharmaceutical manufacturing. As we continue advancing our mission of producing life-saving antibiotics on American soil, we believe his leadership will play a key role in our delivery of these essential medications."

Prior to joining USAntibiotics, Wesoloski held an array of executive leadership and technical roles, including positions with Regor Pharmaceuticals, Gan & Lee Pharmaceuticals, Takeda Pharmaceuticals and TransCode Therapeutics.

About USAntibiotics

USAntibiotics is the only U.S. manufacturer of Amoxicillin and Amoxicillin Clavulanate, commonly known as Amoxil® and Augmentin®. Based in Bristol, Tennessee, it operates a world-class, 394,000 square foot antibiotics production facility with the sole focus of making quality, life-saving antibiotics widely available for the benefit of all Americans. USAntibiotics is part of the Jackson Healthcare® family of companies. For more information, visit www.us-antibiotics.com.


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: